DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Ginkgo Bioworks Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.07−0.20 (-1.95%)
Close on Oct 19, 2026
- Market cap
- $625.29M
- P/E (TTM)
- –
- Dividend yield
- –
Ginkgo Bioworks Holdings, Inc. revenue by segment
By business segment
| Revenue | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell Engineering | $132.75M | $141.53M | $187.24M | $184.31M | $173.97M | $166.16M | $128.25M | $137.32M | $143.53M | $169.81M | $157.32M | – | 78.0% | -23.7% |
| Biosecurity | – | – | – | – | – | $51.79M | $56.09M | $71.37M | $107.92M | $145.17M | $168.64M | – | – | – |
| Operating income | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biosecurity | -$18.93M | -$24.63M | -$25.96M | -$24.59M | -$30.62M | -$32.55M | -$27.53M | -$24.12M | -$3.19M | $9.03M | $9.86M | – | -38.2% |
| Cell Engineering | -$95.53M | -$116.40M | -$84.82M | -$157.90M | -$218.57M | -$229.90M | -$321.07M | -$329.76M | -$363.62M | -$370.90M | -$357.08M | – | -56.3% |
| Cell Engineering and Biosecurity | -$114.46M | -$141.03M | -$110.77M | -$182.49M | -$249.19M | -$262.44M | -$348.60M | -$353.88M | -$366.82M | -$361.87M | -$347.22M | – | -54.1% |
By product or service
| Revenue | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | – | – | $43.57M | $53.10M | $53.07M | $51.79M | $49.59M | $54.09M | $78.98M | $103.79M | $128.56M | $200.56M | – | – |
| Product | – | – | – | – | $0 | $0 | $6.50M | $17.28M | $28.95M | $41.38M | $40.08M | $33.17M | – | – |
| Cell Engineering | – | – | $187.24M | $184.31M | $173.97M | $166.16M | $128.25M | $137.32M | $143.53M | $169.81M | $157.32M | $156.27M | – | – |
By region
From the segment and revenue-disaggregation notes of Ginkgo Bioworks's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.